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Agnoprotein is required for the successful completion of the JC virus (JCV) life cycle and was previously
shown to interact with JCV large T-antigen (LT-Ag). Here, we further characterized agnoprotein’s
involvement in viral DNA replication. Agnoprotein enhances the DNA binding activity of LT-Ag to the viral
origin (Ori) without directly interacting with DNA. The predicted amphipathic a-helix of agnoprotein plays
a major role in this enhancement. All three phenylalanine (Phe) residues of agnoprotein localize to this
a-helix and Phe residues in general are known to play critical roles in protein–protein interaction, protein
folding and stability. The functional relevance of all Phe residues was investigated by mutagenesis. When
all were mutated to alanine (Ala), the mutant virus (F31AF35AF39A) replicated signiﬁcantly less efﬁciently
than each individual Phe mutant virus alone, indicating the importance of Phe residues for agnoprotein
function. Collectively, these studies indicate a close involvement of agnoprotein in viral DNA replication.
& 2012 Elsevier Inc. All rights reserved.Introduction
The integrity and proper functioning of living cells depend on
highly organized and sophisticated interactions among their macro-
molecules including proteins. Upon infection, viruses often hijack
these interactions for their own beneﬁt. To understand the roles of
JCV agnoprotein in an infected cellular environment, it is central to
identify and characterize its interaction parameters with its part-
ners. Agnoprotein encoded by JCV late genome was previously
shown to interact with a number of viral and cellular proteins,
including JCV large T-antigen (LT-Ag) (Safak et al., 2001), small
t-antigen (Sm t-Ag) (Sariyer et al., 2008), p53 (Darbinyan et al.,
2002), YB-1 (Safak et al., 2002), FEZ1 (Suzuki et al., 2005) and HP1-a
(Okada et al., 2005). JCV agnoprotein is a small (71 aa), highly basic
phosphoprotein (Khalili et al., 2005; Sariyer et al., 2006) and has
been implicated in many different aspects of the JCV life cycle,
including viral replication (Safak et al., 2001), transcription (Safak
et al., 2001), encapsidation (Sariyer et al., 2006), functioning as
viroporin (Suzuki et al., 2010b) and promotion of the transport of
virions from nucleus to cytoplasm (Okada et al., 2005; Suzuki et al.,
2005) indicating that it is a multifunctional protein. In addition, it
has also been shown to deregulate cell cycle progression in that cellsll rights reserved.which stably express agnoprotein largely accumulate at the G2/M
phase of the cell cycle (Darbinyan et al., 2002). Despite these
previous reports and intense research, the regulatory role of this
protein in viral replication cycle has yet to be fully understood.
The agnoprotein sequences from other polyomaviruses, includ-
ing SV40 and BK virus (BKV) show high identity and similarity to
that of JCV agnoprotein (Safak et al., 2001). For example, there is 82%
identity and 93% similarity between JCV and BKV agnoprotein
sequences; and these are 60% and 79%, respectively between JCV
and SV40 agnoproteins (Altschul et al., 1997). Like JCV agnoprotein,
the agnoprotein of SV40 and BKV was also previously implicated to
be involved in different aspects of viral replication cycle, including
transcription, translation, virion production and maturation of the
viral particles (Alwine, 1982; Haggerty et al., 1989; Hay et al., 1982;
Hou-Jong et al., 1987; Johannessen et al., 2008; Margolskee and
Nathans, 1983; Moens et al., 2011; Myhre et al., 2010; Ng et al.,
1985; Unterstab et al., 2010).
Besides agnoprotein, JCV encodes a limited number of regula-
tory proteins, including LT-Ag, Sm t-Ag and T0-proteins (Bollag
et al., 2000; Frisque et al., 1984; Saribas et al., 2010) and
investigation of their regulatory roles is critically important for
understanding the progression of the fatal human brain disease,
progressive multifocal encephalopathy (PML). PML results from
the lytic infection of oligodendrocytes, a subset of glial cells in the
central nervous system (CNS), by JCV. This virus is a ubiquitous
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asymptomatically infected by this virus in early childhood world-
wide. The virus undergoes a latency period after initial infection
and reactivation mainly occurs in patients with immunosuppres-
sive conditions (1–5%), including in those with AIDS (Berger,
2011; Major et al., 1992). However, recently scientiﬁc community
was also surprised by the emergence of PML in a very small
percent of the immune disorder patients including those of
multiple sclerosis (MS) and severe psoriasis (Crohn’s disease)
who underwent an immunosupressive immune therapy—treating
patients with speciﬁc monoclonal antibodies (natalizumab and
efalizumab, respectively) directed against certain cell surface
receptors of T and B cells (Kleinschmidt-DeMasters and Tyler,
2005; Langer-Gould et al., 2005; Van Assche et al., 2005).
Occurrence of all these new PML cases in such patient population
indicates that alterations in either arm of immune system may
provide with a supporting environment for reactivation of JCV
virus in certain MS and Crohn’s disease patients. The rationale
behind using these antibodies in MS and Crohn’s disease cases
was to prevent extravasation of T cells into the brain and
inﬁltration of B cells into the layers of the skin, respectively by
blocking several cell surface receptors on each cell type. It was
expected to down-regulate the harmful effects of these immune
cells in target organs. Natalizumab, for example, targets a4
integrin, which forms heterodimer complexes when complexed
with integrin b1 (a4b1, also known as VLA-4) or with integrin b7
(a4b7) on both B and T cells. Both complexes serve as attachment
ligands for vascular cell adhesion molecules (VCAM) on endothe-
lial cells, thus preventing T cells from extravasation into the brain
or gut. Another monoclonal antibody, efalizumab, binds to CD11a,
an integrin molecule on B and T cells and blocks the attachment
of both cell types to the intercellular adhesion molecules (ICAM)
on endothelial cells and prevents their inﬁltration into the layers
of the skin (Kleinschmidt-DeMasters and Tyler, 2005; Langer-
Gould et al., 2005; Saribas et al., 2010; Van Assche et al., 2005). As
a result, treatment of T and B cells with speciﬁc antibodies
appears to cause harmful effects on these immune cell popula-
tions and subsequently fosters conditions for reactivation of JCV
in certain immunocompromised patients and leads to the onset
of PML.
Agnoprotein is a mainly cytoplasmic protein with high con-
centrations accumulated around the perinuclear area of the
infected cells and a small amount of it is consistently found in
the nucleus of the infected cells (Safak et al., 2002). This suggests
regulatory roles for this protein in the nucleus. Characterization of
agnoprotein’s interactions with its targets is essential for under-
standing of its roles in viral replication cycle. Such detailed
characterizations will provide us new opportunities to develop
novel therapeutics against this protein. Our previous studies
characterized the interaction of agnoprotein with LT-Ag and
demonstrated that agnoprotein targets the helicase domain of
JCV LT-Ag (Safak et al., 2001) and does not require DNA or RNA for
interaction with LT-Ag. Recently, we also showed that the JCV and
SV40 with null mutants of agnoprotein cannot sustain their
replication cycle although the mutant viruses were shown to be
successfully released from the infected cells (Sariyer et al., 2011).
It was interesting to observe, however, that the majority of
the released virions were deﬁcient in DNA content, which may
explain, at least in part, why agnoprotein null mutants were
unable to continue to their viral propagation cycle (Sariyer et al.,
2011). More recently, we discovered that agnoprotein forms
highly stable, SDS-resistant homodimers and oligomers; and the
17–42 amino acid region of agnoprotein is responsible for this
property (Saribas et al., 2011). The crystal structure of JCV
agnoprotein is unknown. However, 3D computer modeling stu-
dies suggests that the 17–42 amino acid region is involved informing an amphipathic a-helical structure (Saribas et al., 2011).
This region contains a Leu/Ile/Phe-rich domain (aa 28–39), mainly
consisting of Leu, Ile and Phe. Interestingly, all three Phe residues
(Phe31, Phe35 and Phe39) of agnoprotein localize to this Leu/Ile/
Phe-rich domain. The negatively charged residues, Glu34 and
Asp38, are also interspersed within this domain.
Phenylalanine residues have been reported to play diverse but
important regulatory roles in functions of many different proteins
through hydrophobic interactions [pi(p)–pi(p) stacking] (Bowden
et al., 2008; Brinda et al., 2002; Dhe-Paganon et al., 2004; King
et al., 2011; Milardi et al., 2011). These residues were also found
to be involved in ‘‘cation-p’’ interactions which could take place
between Phe and charged residues (Arg or Lys or His) (Gallivan
and Dougherty, 1999; Pless et al., 2008; Pletneva et al., 2001; Shi
et al., 2002a, 2002b). Recent reports also indicate that Phe
residues can be involved in ‘‘anion-p’’ interactions (Jackson
et al., 2007; Philip et al., 2011). All these interactions mediated
by Phe residues are known to contribute to (i) the protein-protein
interactions at the protein interfaces, (ii) protein folding and
stability (Gallivan and Dougherty, 1999; Pless et al., 2008;
Pletneva et al., 2001; Shi et al., 2002a, 2002b). Based on the
reported contribution of the phenylalanine residues in the litera-
ture and the positioning of all three Phe residues within the
hydrophobic pocket of agnoprotein, we reasoned that they may
also play important structural and functional roles in the biology
of agnoprotein in the infected cells.
In this report, we show that agnoprotein induces DNA binding
activity of LT-Ag to Ori without directly interacting with DNA and
that the predicted main a-helix domain of the protein plays a
major role in this induction. Upon mutation of each Phe residue to
Ala, agnoprotein mostly lost its ability to enhance DNA binding
activity of LT-Ag. Protein-protein interaction studies (GST-pull
down) demonstrated that interaction of each agnoprotein mutant
(F31A, F35A and F39A) with LT-Ag signiﬁcantly decreased com-
pared to that of WT, which is consistent with our ﬁndings from
the DNA binding studies. More importantly, the level of the viral
DNA replication signiﬁcantly diminished when all three Phe
residues were simultaneously mutated to Ala compared to a
slight decrease, which was observed for individual mutants,
indicating the importance of a combinatorial effect of Phe
residues on agnoprotein function. Additionally, results from
immunocytochemistry studies suggest that Phe residues also
contribute to agnoprotein function by assisting to its strategic
distribution in the infected cells, mostly accumulating around the
perinuclear region.Results
Localization of agnoprotein in infected cells
Agnoprotein is a mainly cytoplasmic protein with high concen-
trations accumulating in the perinuclear region of the infected cells.
However, it has been consistently observed that a small amount
of this protein can be detected in the nucleus with conventional
ﬂuorescence microscopy studies (Safak et al., 2002). Prediction
studies show that agnoprotein has a weak bipartite nuclear localiza-
tion signal (Dingwall and Laskey, 1986; Dingwall and Laskey, 1991;
Sigrist et al., 2010) localized to the N-terminus region of the protein
which supports our previous observations (Safak et al., 2002)
(Fig. 1A). To conﬁrm its nuclear localization, we examined the co-
localization of agnoprotein with VP1 and LT-Ag by employing
deconvolution microscopy. This technique allows us to examine
different cross sections of the infected cells similar to those obtained
using confocal ﬂuorescence microscopy studies. For this purpose,
SVG-A cells were infected with JCV Mad-1 strain, ﬁxed with cold
Agno/VP1VP1Agno
Agno/LT-AgLT-AgAgno
10 201 7160504030
Bipartite nuclear
localization signal
Leu/Ile/Phe-rich
domain
Fig. 1. (A) Primary structure of JCV agnoprotein. A predicted weak bipartite nuclear localization signal and the Leu/Ile/Phe-rich domain involved in dimer and oligomer
formation are indicated. (B) Localization of agnoprotein in infected cells. SVG-A cells were transfected/infected with JCV Mad-1 strain, plated on glass chamber slides and
ﬁxed with cold acetone at day 15 posttransfection. Cells were incubated with 5% bovine serum albumin (BSA) prepared in incubation buffer (PBS, 0.1% Tween 20, PBST) for
2 h to reduce the primary antibody binding. Then, cells were washed with the same incubation buffer for 3 times with 10 min intervals and subsequently incubated with a
combination of anti-Agno (rabbit polyclonal, 1:200 dilution) (Del Valle et al., 2002) plus anti-JCV LT-Ag (Ab2000, mouse monoclonal, 1:50 dilution) (Bollag and Frisque,
1992) or anti-Agno (rabbit polyclonal, 1:200 dilution) plus VP1 (PAB597, mouse monoclonal, 1:200 dilution) (Saribas et al., 2011) primary antibodies for overnight as
described in the Materials and methods section. Cells were subsequently washed with incubation buffer three times in 10 min intervals. Cells were then incubated with a
combination of FITC-conjugated anti-rabbit goat IgG plus Rhodamine-conjugated anti-mouse goat IgG for 45 min, washed three times with incubation buffer, mounted
using Vectashield mounting media (Vector Laboratories Inc., Burlingame, CA) and analyzed under a deconvolution microscope (Nikon Eclipse TE300).
A.S. Saribas et al. / Virology 433 (2012) 12–2614acetone at 15d posttransfection, probed with appropriate primary
and secondary antibodies as indicated in the ﬁgure legend 1B and
examined under a deconvolution microscope. As shown in Fig. 1B,
agnoprotein localizes mostly to the perinuclear and cytoplasmic
region of the cells but a small portion of the protein (approximately
15–20%, determined by the statistical analysis software which is
incorporated into the operating software of deconvolution micro-
scope) was also found to localize to the nucleus with LT-Ag (Fig. 1B),
which is consistent with our previous studies (Safak et al., 2002). In
support of these observations, recent confocal microscopy and cell-
membrane fractionation studies by Suzuki et al., also demonstrated
a heavy perinuclear localization of agnoprotein in JCV-infected cells,
co-localizing with endoplasmic reticulum (ER) markers, including
calreticulin and BiP (Suzuki et al., 2010a). These investigators have
also examined the impact of several agnoprotein N-terminal
mutants on agnoprotein distribution. Some of these mutants include
those from the nuclear localization signal (NLS) region of the
protein. Mutation of the Arg8Lys9 residues to AlaAla did not affect
the targeting of the protein to ER. That is, this mutant maintained
some of its localization to ER. However, mutation of the Lys22Ly-
s23Arg24 residues to AlaAlaGly resulted in loss of such an activity,
suggesting that some of the basic residues located within the NLS
region of agnoprotein are important for ER targeting (Suzuki et al.,
2010a). We also examined the co-localization of agnoprotein with
VP1 in a similar manner using appropriate primary and secondary
antibodies. Taken together, our results conﬁrmed previous reports inthat a small portion of agnoprotein expressed in the infected cells
also localizes to the nucleus, suggesting a possible role for agnopro-
tein in the nucleus.Agnoprotein enhances LT-Ag binding to Ori
LT-Ag is the major regulatory protein of JCV and involved in both
viral DNA replication (Lynch and Frisque, 1990; Lynch and Frisque,
1991; Lynch et al., 1994; Tavis and Frisque, 1991) and viral gene
transcription (Khalili et al., 1987; Lashgari et al., 1989; Safak et al.,
2001). It shows signiﬁcant sequence homology to the LT-Ag of SV40
and BKV, with the greatest divergence occurring within the carboxy-
terminal region (Fanning and Knippers, 1992; Frisque et al., 1984).
Biochemical and genetic analyses have shown that SV40 LT-Ag
interacts with speciﬁc nucleotide sequences within the viral
origin of DNA replication (Ori) by forming a double hexamer in
an ATP-dependent manner, unwinds the Ori DNA sequences
(Borowiec et al., 1990; Fanning and Knippers, 1992) and thereby
creates a replication bubble. Then cellular DNA polymerase
a-primase is recruited to the DNA replication initiation sites along
with other replication factors. The elongation process is regulated
by the helicase-ATPase activity of LT-Ag (DePamphilis, 1986;
Stillman, 1994). JCV LT-Ag appears to behave similarly during the
viral DNA replication as described for SV40 LT-Ag (Bollag et al.,
1996; Lynch and Frisque, 1990, 1991; Lynch et al., 1994).
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the infected cells (Fig. 1B) and previously reported interaction of
agnoprotein with the helicase domain of JCV LT-Ag Safak et al.
(2001) suggested that agnoprotein may be involved in regulation
of LT-Ag function, perhaps through inﬂuencing LT-Ag binding to
Ori. We explored this possibility in vitro by employing a band
shift assay. In this assay, we used recombinant proteins (agno-
protein and LT-Ag) and a double-stranded nucleotide probe,
which encompasses 5064–5115 nucleotide region of JCV which
completely overlaps with BS I (binding site I) and IR (inverted
repeat) regions of JCV Ori, respectively as indicated in Fig. 2A
(Lynch and Frisque, 1990). As expected, LT-Ag formed complexes
with Ori sequences (Fig. 2B, lane 2). The multiple banding
patterns that we observed are most likely due to the interaction
of monomeric and different multimeric forms of LT-Ag with DNA
(Borowiec et al., 1990; Fanning and Knippers, 1992).
Next, we analyzed whether agnoprotein inﬂuences the DNA
binding activity of LT-Ag to its target sequences on the Ori probe.
Surprisingly, simultaneous addition of the increasing concentra-
tion of recombinant GST-Agno to the reaction mixture signiﬁ-
cantly enhanced the binding activity of LT-Ag to Ori (Fig. 2B,
compare lane 2 with 6 and 7) in a dose dependent manner,
although agnoprotein alone did not show any indication of
binding to Ori (lane 8), emphasizing the inﬂuence of agnoprotein
on LT-Ag binding to DNA. However, addition of agnoprotein to the1 5432 876
505050LT-Ag (ng): - - 5050 -
DNA-Protein
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GST (μg): 0.5- - 1.5 - - -1.5
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Fig. 2. JCV agnoprotein enhances LT-Ag binding to Ori sequences. (A) Structure of the p
recognition sites. The positions of binding sites I (BS I) and II (BS II) are also indicated. Th
identiﬁed by an open bar. Position of the probe used in the band shift assays is mark
NC_001699). (B) Band shift assay. The double-stranded nucleotide encompassing nt 50
and methods section and gel puriﬁed. The labeled probe (40,000 cpm/lane) was incub
proteins as indicated. DNA-protein complexes were then separated on a 6% native polya
on the gel. (C) Competitive band shift and antibody super-shift assay. Labeled probe was
amounts of unlabeled oligonucleotide (Comp.) (1 ng and 5 ng, lanes 3 and 4, respectivel
serum (NMS) (2 mg, lane 5) or a-LT-Ag (2 mg, Ab-2) antibody as indicated. In lane 1, prob
a 6% polyacrylamide gel under non-denaturing conditions and analyzed by autoradiogreaction mixture did not alter the banding pattern or mobility
of the LT-Ag/Ori complexes other than enhancing the binding
activity of LT-Ag. This is consistent with our previous ﬁndings,
where we demonstrated that Agno/LT-Ag interaction occurs off
the DNA by co-immunoprecipitation assays (Safak et al., 2001).
We believe that a similar interaction is most likely taking place in
our current band shift assays as well. That is, these two proteins
interact with each other off the DNA and this interaction may
result in a conformational change on LT-Ag which subsequently
leads to more efﬁcient binding of LT-Ag to its target sequences on
DNA (Fig. 8). Under identical reaction conditions, we tested the
speciﬁcity of the agnoprotein-mediated enhancement of LT-Ag
binding to DNA by using the GST protein in the binding reactions.
In this regard, addition of GST alone to the binding reaction did
not result in a considerable level of induction (Fig. 2, lanes 3
and 4) compared to that observed for GST-Agno (Fig. 2, lanes 6
and 7). This suggests that the binding activity of LT-Ag to its target
sequences is speciﬁcally stimulated by agnoprotein but not GST
(compare lane 4, with lane 7). GST alone did not interact with the
probe (Fig. 2, lane 5). Collectively, these results demonstrate that
the binding activity of JCV LT-Ag to its target sequences within Ori
is speciﬁcally enhanced by JCV agnoprotein.
We further examined the speciﬁcity of interaction of LT-Ag
with the probe by competitive band shift and antibody super-shift
assays. The Ori probe was incubated with LT-Ag protein in1 5432 6
505050LT-Ag (ng): - 5050
Comp. (ng): 1- - 5 --
Ab: ---- NM
S
α-
LT
-A
g
Supershift
Free probe
utative JCV core origin of replication. Arrows indicates the positions of JCV LT-Ag
e inverted repeat region (IR) is marked by a solid bar and the AþT-rich tract (AT) is
ed by a thin line which encompasses the nucleotides of 5064–5115 (JCV Mad-1,
64–5115 Mad-1 was end-labeled with g-[32P]-dATP as described in the Materials
ated with different combinations and amounts of JCV LT-Ag, GST and GST-Agno
crylamide gel and visualized by autoradiography. In lane 1, probe alone was loaded
incubated with ﬁxed amount of LT-Ag (50 ng/lane) as indicated plus with different
y). In addition, the reaction mixture was also incubated with either normal mouse
e alone was loaded on the gel. DNA-protein-antibody complexes were separated on
raphy.
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of unlabeled competitor DNA (Fig. 2C, lanes 3 and 4). It was
observed that, wild-type Ori DNA efﬁciently competes with the
labeled Ori probe for LT-Ag binding (Fig. 2C, lanes 3 and 4).
Reaction mixture was also incubated with either a speciﬁc anti-
body directed against LT-Ag or with normal mouse serum (NMS)
as indicated. While a-LT-Ag antibody super-shifted the protein-
DNA complexes (compare lane 5 with 6), the normal mouse
serum (NMS) did not have a noticeable effect on the migration
pattern of LT-Ag-Ori complexes. As a result, both the competitive
band shift and the antibody super-shift assays conﬁrm the
speciﬁcity of LT-Ag binding to Ori.The region between amino acids 18-36 is important for stimulation of
LT-Ag binding to Ori
Next, we attempted to identify the region(s) of agnoprotein
responsible for the enhancement of LT-Ag binding to Ori. For
this purpose, a previously created series of deletion mutants of
agnoprotein were expressed as GST fusion proteins in bacteria
(Safak et al., 2001), afﬁnity puriﬁed, dialyzed against DNA binding
buffer as described in the Materials and methods section and
used in a band shift assay. A recombinant JCV LT-Ag alone
was incubated with a double-stranded probe (Fig. 3A, lane 2).
A labeled DNA probe plus recombinant LT-Ag was also incubated
in combination with puriﬁed GST protein alone (lane 3) or with
GST-Agno (WT) (lane 4, 1–71 FL) or Agno deletion mutants fused
to GST (lanes 5–8) as indicated. Formed complexes were then
separated on a 6% native non-denaturing gel and analyzed
by autoradiography. As shown in Fig. 3A, consistent with the
observations from Fig. 2B, LT-Ag binds to Ori sequences but
the addition of GST alone to the binding mixture does not
signiﬁcantly affect the LT-Ag binding to DNA (lane 3). Similarly,1 5432
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Fig. 3. The region between amino acids 18–36 of agnoprotein is important for induced b
or LT-Ag in combination with GST (0.5 mg, lane 3) or LT-Ag in combination with GST-Agn
each, lanes 5–8) as indicated. DNA-protein complexes were separated on a 6% polyacrylam
In lane 1, probe alone was loaded on the gel. (B) Analysis of GST-Agno FL and agnoprot
followed by coomassie blue staining. Degradation products of GST-Agno proteins were etwo N-terminal deletion mutants of agnoprotein (aa 37–71 and aa
55–71) did not show any signiﬁcant effect on the enhancement of
LT-Ag binding either (lanes 7 and 8). However, the other two
deletion mutants that retained N-terminal 54 amino acids (aa 1–54,
lane 5) and C-terminal 53 amino acids (aa 18–71, lane 6)
enhanced the binding activity of LT-Ag to the Ori, at least, as
strongly as WT did. These ﬁndings suggest that the agnoprotein
region between aa 18 and 36 is important for the stimulation of
LT-Ag binding to Ori. Interestingly, this region of agnoprotein, as
previously reported, is also involved in interaction with JCV LT-Ag
(Safak et al., 2001), JCV Sm t-Ag (Sariyer et al., 2008), p53
(Darbinyan et al., 2002) and Yb-1 (Safak et al., 2002); and in
formation of SDS-resistant dimeric and oligomeric structures
(Saribas et al., 2011). SDS-PAGE analysis of the JCV agnoprotein
mutants followed by coomassie staining is shown in Fig. 3B.Analysis of the individual Phe mutants (F31A, F35A or F39A) by
immunocytochemistry and band shift assays
Our recent work demonstrated that 17–42 amino acid region
of agnoprotein participates in SDS-resistant dimer/oligomer for-
mation and adopts a predicted amphipathic a-helix structure
(Saribas et al., 2011) and Fig. 4A illustrates the predicted 3D
structure of agnoprotein by computer modeling (Roy et al., 2010).
Interestingly, this a-helix contains a Leu/Ile/Phe-rich domain (aa
28–39), consisting of multiple Leu, Ile and Phe residues and two
charged residues, Glu34 and Asp38, interspersed within amino
acids of the Leu/Ile/Phe-rich domain (Fig. 1A and Fig. 4B). The
predicted amphipathic nature of the a-helix can accommodate the
spatial conformation of the negatively charged residues (Glu34 and
Asp38) in the Leu/Ile/Phe-rich domain. An amphipathic nature of
the a-helix was also reported for BKV agnoprotein (Unterstab et al.,
2010). All Phe residues (Phe31, Phe35 and Phe39) of agnoprotein8
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Fig. 4. Structural model of agnoprotein and immunocytochemical analysis of F31A, F35A and F39A mutants. (A) Three-D model of JCV agnoprotein was predicted using
I-Tasser program (Roy et al., 2010). Positions of the three Phe residues are indicated on the a-helical structure. (B) Alignment of SV40, BKV and JCV agnoprotein sequences.
(C) Immunocytochemical analysis of F31A, F35A and F39A mutants of agnoprotein in the infected cells. SVG-A cells were transfected/infected either with JCV Mad-1 WT or
JCV Mad-1 Agno-F31A or JCV Mad-1 Agno-F35A or JCV Mad-1 Agno-F39A mutant genome and at day 5, cells were ﬁxed with cold acetone and blocked with 5% BSA
prepared in PBST for 2 h. Cells were then incubated with a combination of a-Agno (rabbit polyclonal, 1:200 dilution) (Del Valle et al., 2002) and a-VP1 (PAB597, mouse
monoclonal, 1:200 dilution) (Saribas et al., 2011) overnight. Cells were ﬁrst washed with PBST three times with (10 min intervals) and incubated with the combination of
FITC-conjugated anti-rabbit goat and Rhodamine-conjugated anti-mouse goat secondary antibodies for 45 min. Cells were ﬁnally washed with PBST three times with
10 min intervals, mounted with mounting media and examined under a ﬂuorescence microscope.
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residues are conserved among agnoproteins from JCV, BKV and
SV40, the position of JCV F31 is shifted to the position 29 in BKV
and SV40 (Fig. 4B). Importantly, Phe residues, in general, are
known to play diverse but important roles in the function of many
different proteins through hydrophobic interactions and possibly
through ‘‘cation-p’’ and ‘‘anion-p’’ interactions (Gallivan and
Dougherty, 1999; Jackson et al., 2007; Philip et al., 2011; Pless
et al., 2008; Pletneva et al., 2001; Shi et al., 2002a, 2002b). Such
interactions mediate protein-protein interactions at protein inter-
faces and also aid to the folding and stability of many different
proteins (Bowden et al., 2008; Gallivan and Dougherty, 1999;
Jackson et al., 2007; King et al., 2011; Milardi et al., 2011; Philip
et al., 2011; Pless et al., 2008; Pletneva et al., 2001; Shi et al., 2002a,
2002b). As such, it is conceivable that the Phe residues of
agnoprotein may participate in such interactions to form homo-
dimers between its monomers or heterodimers between agnopro-
tein and other cellular or viral proteins and thereby contribute to
the function of agnoprotein during the viral replication cycle.
We then assessed the contribution of each Phe residue to
agnoprotein function by site-directed mutagenesis followed by
immunocytochemistry assays. As shown in Fig. 4C, contrary to our
ﬁndings for WT agnoprotein (mostly shows a perinuclear distribu-
tion), mutant agnoproteins were found to be more evenly dis-
tributed within the cytoplasm and lost their high level of
accumulation around the perinuclear area (Fig. 4C). This contrast-
ing observation suggests that these Phe residues may play a role in
a preferential and strategic distribution of agnoprotein around the
perinuclear region. These altered distribution patterns also suggest
that agnoprotein mutants maybe lost or gained some new abilities
to interact with their partners, which subsequently modiﬁed their
distribution patterns in the infected cells. Another peculiarity
regarding these individual Phe mutants was that the majority of
cells infected with the mutant viruses were found to have a larger
cell volume than those infected withWT. We currently do not have
an explanation for this interesting observation.
We also examined the effect of Ala substitutions for all three
individual Phe residues on agnoprotein-enhanced DNA binding
activity of LT-Ag by gel shift assays. All three individual Phe
mutants (F31A, F35A, F39A) and WT agnoprotein were produced
as GST-fusions in bacteria and afﬁnity puriﬁed as described in the
Materials and methods section. These mutant proteins were then
used in band shift assays together with baculovirus-produced
recombinant LT-Ag as described in ﬁgure legend 5. All individual
substitution mutants of agnoprotein failed to stimulate LT-Ag
binding activity to Ori at varying degrees (Fig. 5A–C). Comparison
of the band intensities of the DNA-protein complexes of WT
agnoprotein with those of mutants clearly demonstrated this
difference (compare lane 5 with 8 in each panel).
In parallel to DNA binding assays, we also examined the ability
of interaction of each agnoprotein point mutant (F31A, F35A
and F39A) with LT-Ag by employing a GST-pull down assay as
described in the Materials and methods section. This assay is a
powerful technique to test the interaction between two or more
proteins. As previously reported (Safak et al., 2001), WT agnopro-
tein strongly interacts with LT-Ag off the DNA (Fig. 5D, lane 3).
The strength of this interaction signiﬁcantly decreased when each
agnoprotein point mutant (F31A, F35A and F39A) was incubated
with LT-Ag (43-fold decrease, compare lane 2 with lanes 4–6),
which is consistent with our ﬁndings from our DNA binding
assays (Fig. 5A–C). In DNA binding assays, we observed that WT
agnoprotein strongly induces LT-Ag binding to Ori (Fig. 2A) but
each agnoprotein point mutant (F31A, F35A and F39A) lost much
of this ability (Fig. 5A–C). The lack of interaction between LT-Ag
and GST alone (lane 2) demonstrates the speciﬁcity of the
interaction between agnoprotein and LT-Ag and serves as anegative control in this protein–protein interaction (GST-pull
down) assay.
Functional analysis of agnoprotein Phe mutants
We next examined the impact of each Phe mutant (F31A,
F35A and F39A) on the viral DNA replication cycle in the viral
background measured by DpnI assay. Mutant genomes were
individually transfected/infected into SVG-A cells and low mole-
cular weight DNA was isolated at 5 and 15 day posttransfection.
DNA samples were then digested with BamHI/DpnI restriction
enzymes. BamHI linearizes the input and replicated DNA; and
DpnI is known to speciﬁcally digest out the transfected DNA
(bacterially produced and methylated input DNA) while keeping
the newly-replicated viral DNA intact (Hirt, 1967). DNA samples
were then analyzed by Southern blotting as described in the
Materials and methods section. As shown in Fig. 6A, the levels of
the viral DNA replication for JCV Agno mutants, F35A and F39A,
modestly decreased (30% and 26% decrease, respectively)
(compare lane 6 to lanes 8 and 9), while that for F31A remained
similar to WT (11% decrease) (compare lane 6–7). These
ﬁndings are consistent with those found with DNA binding assays
(Fig. 5A–C), where it was observed that both F35A and F39A
mutants almost completely lost their ability to enhance LT-Ag
binding to Ori (Fig. 5B and C), whereas F31A mutant slightly
retained such an ability (Fig. 5A).
Combinatorial effect of all three Phe mutants on agnoprotein function
In order to get more insight into the roles of Phe residues in
agnoprotein function, a cumulative effect of all Phe residues,
where all three Phe residues were converted into Ala (triple Phe
mutant), was analyzed by immunocytochemistry and replication
assays. It was interesting to observe that each individual Phe
mutant inﬂuenced the distribution pattern of agnoprotein in the
infected cells. That is, in contrast to the distribution pattern of WT
agnoprotein – mostly accumulating around the perinuclear area
and localizing to nucleus in small amounts –, all the individual
mutants, however, showed a more uniform distribution pattern
throughout the infected cells. We also wanted to analyze whether
a triple Phe mutant has a similar differential effect on agnoprotein
distribution. To test this possibility, JCV Mad-1 WT and JCV Mad-1
Agno triple Phe mutant was separately transfected/infected
into SVG-A cells and cells were ﬁxed at 15 day posttransfec-
tion and analyzed by immunocytochemistry as described for
Fig. 4C. As expected, WT agnoprotein showed high level of
accumulation around the perinuclear area of the infected cells.
However, the triple Phe mutant lost such ability and showed a
more uniform distribution pattern throughout the infected cells
(Fig. 7A), similar to those observed for each individual Phe mutant
(Fig. 4C).
In parallel, we also analyzed the effect of this triple Phe mutant
on the viral DNA replication cycle in the viral background,
employing DpnI assay. The low molecular weight DNA was
isolated at 5 and 15 day posttransfection. DNA samples were
then analyzed by southern blotting to measure the level of newly
replicated mutant viral DNA relative to that of WT. As shown in
Fig. 7B, the level of the viral DNA replication for the triple Phe
mutant decreased more drastically (3.5 fold, Fig. 7B and C) than
those observed for the individual Phe mutants (Fig. 6A) by 15 day
posttransfection. This observation clearly demonstrates a cumu-
lative negative effect of all the three Phe residues on the viral
DNA replication. In addition, the expression level of agnoprotein
triple mutant was also signiﬁcantly decreased compared to WT
(Fig. 7D), which is consistent with the replication assay data
(Fig. 7B). Taken together, these ﬁndings suggest that Phe residues
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Fig. 5. F31A, F35A and F39A mutants of agnoprotein failed to enhance LT-Ag binding to Ori. (A), (B) and (C) F31, F35 and F39 were substituted with Ala by Quik-ChangeTM
mutagenesis kit and mutant DNA was subcloned into pGEX1lT vector at BamHI/EcoRI sites. Subsequently, the mutant proteins were produced in E. coli and puriﬁed as
described in the Materials and methods section and used in band shift assays as indicated. The band shift assay conditions were identical to those described under the
legend for Fig. 2(A). In lane 1, probe alone was loaded on the gel. (D) Analysis of the interaction of agnoprotein point mutants [GST-Agno (F31A), GST-Agno (F35A) and
GST-Agno (F39A)] with JCV LT-Ag by a GST pull-down assay. Whole-cell extracts prepared from HJC-15b cells, which express JCV LT-Ag constitutively (Raj et al., 1995),
were incubated with either GST alone or GST-Agnoprotein WT or agnoprotein point mutants fused to GST [GST-Agno (F31A), GST-Agno (F35A) and GST-Agno (F39A)] as
described in the Materials and methods section. Beads were washed extensively and proteins interacting with GST or GST-Agno Phe mutants [GST-Agno (F31A), GST-Agno
(F35A) and GST-Agno (F39A)] were resolved by SDS-PAGE and analyzed by Western blotting using anti-LT-Ag antibody (Ab-2). In lane 1, 15 mg of whole-cell extract were
loaded as a positive (þ) control. (E) Analysis of the GST and GST-Agno WT and agnoprotein point mutants [GST-Agno (F31A), GST-Agno (F35A) and GST-Agno (F39A)] by a
10%-SDS-PAGE followed by coomassie staining.
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JCV Mad-1 Agno-F31A, JCV Mad-1 Agno-F35A or JCV Mad-1 Agno-F39A viral DNA genomes (8 mg each). The low-molecular-weight DNA containing both input and
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a 1% agarose gel, transferred onto a nitrocellulose membrane (Bio-Rad) and probed for detection of the newly replicated DNA using a probe prepared from the JCV Mad-1
WT as a template. In lane 1, 2 ng of JCV Mad-1 WT linearized by BamHI digestion was loaded as positive control (þCont.). Replication assays were repeated several times
and a representative result is shown here. (B) Quantitation analysis of Southern blots by a semi-quantitative densitometry method (using NIH Image J program) and
presentation of the results in arbitrary units. The replication efﬁciency of each data point was presented relative to that of WT.
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its structure.Discussion
Agnoprotein is a major regulatory protein of JC virus in
addition to LT-Ag, Sm t-Ag and the T0-proteins (Bollag et al.,
2000, 2010; Frisque et al., 1984; Safak et al., 2001; Sariyer et al.,
2008). In the absence of agnoprotein expression, the replication
cycle of JCV, BKV and SV40 does not proceed efﬁciently (Myhre
et al., 2010; Saribas et al., 2011; Sariyer et al., 2011). Many studies
indicate that agnoprotein is a multifunctional protein and is
involved in different aspects of viral replication cycle, including
transcription and replication (Safak et al., 2001, 2002). While
much has been learned, the precise function of this protein in JCV
infection is not fully understood.
Our DNA binding studies demonstrated that agnoprotein
enhances the DNA binding activity of LT-Ag to Ori without directly
interacting with DNA (Fig. 2A). This is a novel ﬁnding suggesting
that agnoprotein may be involved in viral DNA replication through
interaction with LT-Ag. However, agnoprotein does not seem to
form an apparent ternary complex with LT-Ag/DNA complex under
our band shift assay conditions, because the migration pattern of
DNA-protein complexes was not altered upon addition ofagnoprotein into the binding mixture (Fig. 2B). This is consistent
with our previous reports, where it was shown that agnoprotein
interacts with the helicase domain of LT-Ag without requiring the
presence of DNA molecule for the interaction (Safak et al., 2001).
This observation suggests that (i) interaction of agnoprotein with
LT-Ag off the DNA is sufﬁcient to induce a conformational change
on LT-Ag protein so that LT-Ag binds to its target sequences more
efﬁciently. Agnoprotein is then most likely liberated from LT-Ag/
Agno complex before LT-Ag binds to DNA (Fig. 8). This is, at least,
one of the reasons that agnoprotein is not the part of LT-Ag/DNA
complex. (ii) Alternatively, the interaction between agnoprotein
and LT-Ag/DNA complex is weak and therefore is unstable under
our gel shift running conditions. Nonetheless, the ability of one
protein to inﬂuence the DNA binding capacity of another one has
been well-established. There are many similar interactions
reported in the literature, including the induction of Tst-1 binding
to DNA by HMG-1/Y (Leger et al., 1995), stimulation of the serum
response factor binding to DNA by Phox1 (Grueneberg et al., 1992)
and induction of YB-1 binding to the 23-bp element of JCV
archetype by LT-Ag (Safak et al., 1999).
The observation that agnoprotein does not directly interact
with DNA contrasts with a previously reported case of SV40
agnoprotein (Gilbert et al., 1981). Gilbert et al., reported that SV40
agnoprotein is a DNA binding protein based on the premise that
this protein has a highly basic character containing many
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Fig. 7. Effect of a triple Phe mutant (F31AF35AF39A) on agnoprotein expression and the viral DNA replication in the viral background. (A) Immunocytochemical analysis of
a triple Phe mutant (F31AF35AF39A). SVG-A cells were transfected/infected either with JCV Mad-1 WT or the triple Phe mutant and at day 5, cells were ﬁxed with cold
acetone and blocked with 5% BSA prepared in PBST for 2 h. Then cells were processed for immunocytochemical detection of agnoprotein as described under the legend for
Fig. 4(C). (B) A cumulative effect of all three Phe mutations of agnoprotein on viral DNA replication. DpnI assay for a triple Phe mutant [F31A F35AF39A)¼(T-Phe Mut.). JCV
Mad-1 Agno WT and JCV Mad-1 Agno-(F31A F35A F39A) mutant genomes were transfected/infected into SVG-A cells and low molecular DNA was isolated at the indicated
data points and analyzed by Southern blotting as described for Fig. 6(A). Replication assays were repeated several times and a representative result is shown here.
(C) Quantitation analysis of Southern blots by a semi-quantitative densitometry method (using NIH Image J program) and presentation of the results in arbitrary units. The
replication efﬁciency of the mutant virus was presented relative to that of WT. (D) Western blot analysis. In parallel to Southern blot analysis in 7B, whole-cell extracts
were prepared at day 5 and 15 posttransfection from SVG-A cells transfected/infected with either JCV Mad-1 WT or JCV Mad-1 Agno-(T-Phe Mut.) as indicated, and
analyzed by Western blotting. In this regard, 40 mg s of whole-cell extracts were separated on a 15% SDS-PAGE, transferred onto a nitrocellulose membrane and incubated
with a primary (anti-Agno, polyclonal) (Del Valle et al., 2002) and secondary antibodies. The protein of interest was then detected by using ECL reagent as described in the
Materials and methods section. In lane 1 and 4, whole-cell extracts prepared from untransfected SVGA cells were loaded as negative controls (Cont.).
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inﬂuence its nucleic acid interaction (Gilbert et al., 1981). The
experimental settings employed by Gilbert et al., were somewhat
different than those used in our DNA binding assays. This may
account for the difference in our and their ﬁndings and conclu-
sions. We have used a puriﬁed recombinant protein (GST-Agno)
and a short-labeled synthetic oligonucleotide corresponding to
the BS I and IR region of Ori (Fig. 2A) in our binding assays and
showed that puriﬁed agnoprotein does not directly interact with
DNA (Fig. 2B). In the report by Gilbert et al., however, metaboli-
cally labeled whole-cell extracts prepared from African Green
Monkey Kidney (AGMK) cells infected with SV40 were loaded
onto either a single-stranded or a double-stranded calf thymus
DNA-cellulose columns (Gilbert et al., 1981). The columns were
then consecutively washed with a low salt and high salt buffers;
and various fractions were analyzed by SDS-PAGE followed by
autoradiography. Labeled agnoprotein was only detected in frac-
tions eluted with high salt but not with low salt buffer. Interest-
ingly, many other labeled-proteins, in addition to agnoprotein,
were also detected in the elution fractions, thus making the
conclusions somewhat complicated. Because these results also
suggest a strong possibility that agnoprotein does not necessarily
directly bind to DNA but rather interacts with the cellular
proteins that were retained in the DNA columns due to their
intrinsic DNA binding activities. Therefore, it is possible that
agnoprotein was eluted out along with those proteins and
detected in those fractions.
Agnoprotein has been previously shown to interact with
cellular, (YB-1, FEZ1 and HP1-a, p53) and viral (LT-Ag, Sm t-Ag)proteins (Darbinyan et al., 2002; Okada et al., 2005; Safak et al.,
2001, 2002; Sariyer et al., 2008) and the 18–36 amino acid region
of the protein has been consistently observed to be critical for
such interactions. We have recently reported that the same region
of agnoprotein plays an important role in the viral replication
cycle perhaps through forming highly stable SDS-resistant
dimeric/oligomeric structures (Saribas et al., 2011). In addition,
3D computer modeling suggests that this region is also involved
in forming an a-helical structure (Saribas et al., 2011). This helix
region contains a Leu/Ile/Phe-rich domain (aa 28–39) and two
negatively charged residues, Glu34 and Asp38, are also found to
be present in the same region (Fig. 1A, Fig. 4B). Interestingly, all
three Phe residues (Phe31, Phe35 and Phe39) of JCV agnoprotein
are located in this Leu/Ile/Phe-rich domain. All three Phe residues
of BKV and SV40 agnoproteins also localize to the respective Leu/
Ile/Phe-rich domain of each protein but there are differences
among their positioning compare to those present in JCV agno-
protein (Fig. 4B). The position of Phe31 and Phe39 is conserved
among the agnoprotein of all three polyomaviruses, JCV, BKV and
SV40, but the position of Phe35 of JCV agnoprotein shifted to
position Phe29 in BKV and SV40 agnoprotein (Fig. 4B), indicating
possible differential structural and functional roles for them in
their respective viral replication cycles.
Phenylalanine residues are known to play important roles
in functions of many different proteins, including in mediation
of protein–protein interactions, protein folding and stability
(Bowden et al., 2008; Gallivan and Dougherty, 1999; King et al.,
2011; Milardi et al., 2011; Pless et al., 2008; Pletneva et al., 2001;
Shi et al., 2002a, 2002b). Phe residues accomplish such functions
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Fig. 8. Model for agnoprotein/LT-Ag interaction in the nucleus. Upon translation of the JCV late transcripts (1), agnoprotein mostly localizes to cytoplasm, largely
accumulating around the perinuclear area (2) [Fig. 1(B)] and a small amount of the protein, however, translocates into the nucleus (3), where it interacts with LT-Ag off the
DNA (Safak et al., 2001) and perhaps induces conformational changes on LT-Ag too (6). Subsequently, agnoprotein separates from the LT/Agno complex (4) and liberated
LT-Ag then binds to Ori [Fig. 2(A)] more efﬁciently in a double hexamer manner (7), unwinds DNA and initiates viral DNA replication which may lead to an increased viral
DNA replication (8).
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of the aromatic ring of Phe or ‘‘cation-p’’ interactions (Bowden
et al., 2008; Gallivan and Dougherty, 1999; King et al., 2011;
Milardi et al., 2011; Pless et al., 2008; Pletneva et al., 2001; Shi
et al., 2002) or ‘‘anion-p interactions (Jackson et al., 2007; Philip
et al., 2011) or through the combination of all these three types
of interactions. Such interactions may also take place between
homodimers (agno-agno interaction) or heterodimers (interac-
tion of agnoprotein with its partners in the infected cell) of
agnoprotein and signiﬁcantly contribute to its functions. Based
on these reports, we have then investigated the contribution of
Phe residues to agnoprotein function by site-directed mutagen-
esis. Individual substitution of Phe residues to Ala resulted in
partial or full loss of agnoprotein-mediated enhancement of LT-
Ag binding to Ori (Fig. 5A–C). This loss was more prominent in
the case of individual conversion of Phe35 and Phe39 to Ala than
that of Phe31 to Ala (Fig. 5). Corroborative results were also
obtained when these mutants were tested in viral DNA replica-
tion assays in vivo (Fig. 6A), where it was observed that the level
of the viral DNA replication for F35A and F39A mutants
decreased more prominently than that observed for F31A com-
pared to WT (Fig. 6A). Importantly, the level of viral replication
reduced more drastically compared to WT when all three
Phe residues all together mutated to Ala, which further illus-
trates the importance of Phe residues in agnoprotein function
(Fig. 7A and 7B).
Relatively high level accumulation of agnoprotein around the
prenuclear area and smaller amounts being detected in the nucleus
are the characteristics of agnoprotein distribution pattern in the
infected cells (Fig. 1B, and Fig. 4C). However, this distribution
pattern was altered when Phe mutants of agnoprotein was analyzed
by immunocytochemistry. It was found that all individual as well as
the triple Phe mutants of agnoprotein more evenly distribute
throughout the infected cells rather than primarily accumulating
around the perinucleus area as regularly observed for WT agnopro-
tein. This suggests that Phe residues may direct agnoprotein
strategically to the perinuclear area of infected cells or differentially
interacts with new targets. Additionally, these residues may alsohelp agnoprotein to homodimerize by itself and/or heterodimerize
with other cellular and viral partners to fulﬁll its functions.
Polyomaviruses including JCV, BKV and SV40 encode only a
limited number of regulatory proteins, one of which is agnopro-
tein, and yet these viruses successfully go through their replica-
tion cycles. This suggests that these regulatory proteins perform
more than one function to optimize the viral life cycle. Published
reports indicate that JCV agnoprotein is involved in many aspects
of viral replication cycle, including viral DNA replication (Safak
et al., 2001; Saribas et al., 2011) and transcription (Safak et al.,
2001, 2002; Sariyer et al., 2011). If this is the case, then, the
question arises ‘‘how is such a small protein like agnoprotein able
to achieve so many different functions despite its small size?’’ It
appears that agnoprotein sequence contains many functional
domains strategically packed into a short structure. Any distur-
bances in its sequences may result in severe consequences. For
instance, it was previously reported that conversion of Thr21
[protein kinase C (PKC)-phosphorylation site] alone into Ala on
agnoprotein results in a phenotype that is unable to sustain the
viral replication cycle (Sariyer et al., 2006). It was also recently
found that deletion of either internal amino acids 17–42 (Saribas
et al., 2011) or C-terminal sequences from 51–71 (Akan et al.,
2006) also resulted in phenotypes that are replication incompe-
tent. All these observations suggest that there is a close relation-
ship between the structure and the function of agnoprotein,
which has to be further investigated to determine the details of
such a relationship.
There are many other examples of the small viral proteins
from the literature that have multifunctional characteristics,
including HIV-1 Rev and Vpr. Rev is a 91 aa phosphorylated
nuclear protein and like JCV agnoprotein, it also forms dimers
and oligomers as evidenced by X-ray crystallography studies
(Daugherty et al., 2010a, 2010b). It is involved in the transport
of incomplete spliced RNA molecules from nucleus to cytoplasm.
Rev binds to Rev response elements present in the intron region
of the viral transcripts and functions as both stable dimers and
oligomers as evidenced by 3D structural studies (Daugherty et al.,
2010a, 2010b; DiMattia et al., 2010). Vpr, another small protein
A.S. Saribas et al. / Virology 433 (2012) 12–26 23(96 aa) of HIV, also forms stable dimers as shown by NMR
structural studies (Bourbigot et al., 2005; Morellet et al., 2003),
arrests cells at G2/M phase transition and induces apoptosis
(Bolton and Lenardo, 2007; Cui et al., 2006; Fritz et al., 2008,
2010; Godet et al., 2010; Iordanskiy et al., 2004; Poon et al., 2007),
indicating its multifunctional nature.
Agnoproteins of JCV, BKV and SV40 all form highly stable
dimeric and oligomeric structures (Saribas et al., 2011), functions
of which are currently unknown. However, it is conceivable that
such structures may provide considerable ﬂexibility to agnopro-
tein to diversify its biological functions in the infected cells.
Rough mapping studies of JCV agnoprotein showed that aa
17-42 are important for dimer and oligomer formation property
of agnoprotein (Saribas et al., 2011). In the current study, we have
advanced our understanding of agnoprotein function one step
further by examining its inﬂuence on viral DNA replication and by
particularly focusing on the functional analysis of its Phe residues.
Our future studies will be directed to further dissect out 17–42
aa region of JCV agnoprotein and analyze the contribution of
this region to agnoprotein function. Such detailed studies may
provide us with important clues to design effective inhibitors
against agnoprotein to curb the progression of PML in affected
individuals.Materials and methods
Cell lines
SVG-A is a human cell line established by transformation of
primary human fetal glial cells with an origin-defective SV40 mutant
(Major et al., 1985). These transformed cells do not express either
SV40 viral capsid proteins (VPs) or agnoprotein, but express SV40
LT-Ag. Cells were grown in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum
(FBS) and antibiotics [penicillin/streptomycin (100 mg/ml), ciproﬂox-
acin (10 mg/ml). They were maintained at 37 1C in a humidiﬁed
atmosphere supplemented with 7% CO2.
Plasmid constructs
The cloning of pGEX1lT-Agno (1–71) or GST fusion Agno deletion
mutants [pGEX1lT-Agno (1–54), pGEX1lT-Agno (18–71), pGEX1lT-
Agno (37–71), pGEX1lT-Agno (55–71)] were previously described
(Safak et al., 2001). Agnoprotein-F31, -F35 and -F39 residues were
individually mutated to Ala (A) in the viral background (JCV Mad-1)
using the Quik ChangeTM site-directed mutagenesis kit (Agilent) and
designated as JCV Mad-1 Agno-F31A, JCV Mad-1 Agno-F35A and JCV
Mad-1 Agno-F39A mutant viruses. F31, F35 and F39 residues were
also altogether mutated to Ala in the viral background and designated
as triple Phe mutant [JCV Mad-1 Agno (F31AF35AF39A)]. Each single
mutant of agnogene was also subcloned into pGEX1lT vector at the
BamHI/EcoRI sites by PCR-based cloning and designated as pGEX1l
T-Agno-F31A, pGEX1lT-Agno-F35A, pGEX1lT-Agno-F39A. The integ-
rity of all plasmids was determined by DNA sequencing.
Expression and puriﬁcation of recombinant proteins
A hundred milliliter overnight cultures of Escherichia coli DH5a
cells transformed with plasmids expressing either Glutathione-S-
Transferase (GST) or full length agnoprotein fused to GST [(GST-
Agno (1–71)] or different deletion mutants of agnoprotein fused
to GST [GST-Agno (1–54), GST-Agno (18–71), GST-Agno (37–71),
GST-Agno (55–71)] or different substitution mutants of agnopro-
tein fused to GST [GST-Agno (F31A), GST-Agno (F35A), GST-Agno
(F39A)] or pMAL-C5X-Agno (F31AF35AF39A) were ﬁrst diluted1:10 in fresh Luria-Bertani broth in 1L supplemented with
ampicillin (100 mg/ml) and grown at 37 1C until at an optical
density of 0.5. Bacterial cultures were then induced with 0.3 mM
isopropyl-b-thiogalactopyranoside (IPTG) and incubated for an
additional 2 h at 28 1C. Bacterial cells were harvested by centri-
fugation at 4 1C and pellets were resuspended in 20–40 ml of
PENT lysis buffer containing 20 mM Tris–HCl (pH 8.0), 100 mM
NaCl, 1 mM EDTA, 0.5% Nonidet P-40 supplemented with a cock-
tail of protease inhibitors (Sigma). Bacterial cells were ﬁrst
sonicated and clear cell lysates were prepared by centrifugation
at 12,000g. Lysates were then incubated with 200 ml of 50%
Glutathione-Sepharose 4B resin (GE Health Care) in phosphate
buffered saline (PBS) overnight at 4 1C. GST fusion proteins bound
to beads were puriﬁed by three cycles of washing and centrifuga-
tion with 5 ml of PENT lysis buffer, eluted with glutathione (GSH)
elution buffer (50 mM Tris–HCl, 10 mM reduced GSH, pH 8.0),
dialyzed overnight in band shift sample buffer [12 mM HEPES (pH
7.9), 4 mM Tris–HCl (pH 7.5), 60 mM KCl, 5 mM MgCl2 and
1.0 mM DTT]. JCV LT-Ag was expressed in Sf9 insect cells using
a baculovirus expression system and afﬁnity puriﬁed as pre-
viously described (Bollag et al., 1996). Finally, JCV LT-Ag, GST
and GST-Agno fusion proteins were analyzed by SDS-polyacryla-
mide gel electrophoresis followed by coomassie blue staining to
determine the protein quality.Band shift assays
Band shift assays were carried out as previously described
(Kim et al., 2003; Sadowska et al., 2003). Brieﬂy, a double-
stranded synthetic oligonucleotide encompassing a part of JCV
Mad-1 origin (nt 5064-5115) was end-labeled with [g-32P] ATP
using T4 polynucleotide kinase and gel puriﬁed. Bacterially-
produced and puriﬁed GST alone or GST-Agno (full length or its
mutants) or baculovirus-produced and puriﬁed JCV LT-Ag were
incubated with labeled probe (40,000-cpm/lane) in different
combinations, as described in the respective ﬁgure legends in
50 ml reaction volume, in binding buffer containing 1.0 mg
poly(dI–dC), 12 mM HEPES (pH 7.9), 4 mM Tris–HCl (pH 7.5),
60 mM KCl, 5 mM MgCl2 and 1.0 mM DTT. The reaction mixture
was incubated at 4 1C for 45 min to allow the formation of DNA-
protein complexes. The complexes were then separated on a 6%
polyacrylamide gel in 0.5TBE [1TBE is 89 mM Tris–HCl, (pH
8.0), 89 mM boric acid, and 2 mM EDTA, (pH 8.0)]. The gel was
dried and DNA-protein complexes were detected by autoradio-
graphy. Detailed experimental conditions for all band shift assays
are described in the respective ﬁgure legends.GST afﬁnity chromatography assay (GST pull-down)
GST pull-down assay was performed as previously described
(Safak et al., 2001). Brieﬂy, 2 mg of either GST alone, or GST-AgnoWT
or agnoprotein point mutants fused to GST [GST-Agno (F31A),
GST-Agno (F35A) and GST-Agno (F39A)] immobilized on Sepharose
beads was incubated with 0.3 mg of whole-cell extracts prepared
from HJC-15b cells (Raj et al., 1995) constitutively expressing
JCV LT-Ag in a 300 ml reaction volume for 2 h at 4 1C in lysis buffer
containing 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, and 0.5%
Nonidet P-40. The protein-complexed beads were washed exten-
sively with lysis buffer and resolved by SDS–10% PAGE followed by
Western blot analysis using anti-LT-Ag antibody (Ab-2). Ab-2
monoclonal antibody has been raised against SV40 LT-Ag but
cross-reacts with JCV LT-Ag as well.
A.S. Saribas et al. / Virology 433 (2012) 12–2624Indirect immunoﬂuorescence microscopy
Indirect immunoﬂuorescence microscopy studies were per-
formed as previously described (Sadowska et al., 2003; Sariyer
et al., 2011). Brieﬂy, SVG-A cells were transfected/infected with
respective viral DNA and seeded at subconﬂuency on polylysine-
coated glass chamber slides at speciﬁc dates posttransfection
indicated in the respective ﬁgure legends. The next day, cells
were washed twice with PBS and ﬁxed in cold acetone. Fixed cells
were then blocked with 5% bovine serum albumin in PBS for 2 h,
divided into two groups and incubated with two different anti-
body combinations. In the ﬁrst group, ﬁxed cells were incubated
with anti-agno primary polyclonal rabbit antibody (1–200 dilu-
tion) (Del Valle et al., 2002) plus anti-JCV LT-Ag primary mono-
clonal mouse antibody (Ab 2000) (Bollag and Frisque, 1992)
(1:200 dilution) overnight. Ab 2000 antibody speciﬁcally detects
only JCV LT-Ag, not SV40 and BKV LT-Ag proteins. In the second
group, cells were incubated with anti-agnoprotein primary poly-
clonal antibody (1–200 dilution) plus anti-VP1 primary mono-
clonal (pAB597) antibody (Saribas et al., 2011) (1:200 dilution)
overnight. Antibody dilutions and incubations were performed in
incubation buffer [PBST¼(PBSþ0.01% Tween 200)] buffer. Cells
were then washed three times with PBST buffer for 10-min
intervals and subsequently incubated with a Rhodamine-conju-
gated goat anti-mouse plus ﬂuorescein isothiocyanate (FITC)-
conjugated goat anti-rabbit secondary antibodies (BD bios-
ciences) for 45 min. Finally, the slides were washed three times
with PBST buffer, mounted, and examined under ﬂuorescence
microscope for detection of JCV agnoprotein, JCV LT-Ag and JCV
VP1. The immunocytochemistry analysis of JCV Mad-1 Agno-
F31A, JCV Mad-1 Agno-F35A, JCV Mad-1 Agno-F39A and JCV
Mad-1 Agno (F31AF35AF39A) mutant viruses is described in the
relevant ﬁgure legends.
Replication assays
Replication assays were carried out as previously described
(Sariyer et al., 2011). Brieﬂy, SVG-A cells (2106 cells/75 cm2
ﬂask) were separately transfected/infected either with JCV Mad-1
WT, JCV Mad-1 Agno-F31A, JCV Mad-1 Agno-F35A, JCV Mad-1
Agno-F39A, or JCV Mad-1 Agno (F31AF35AF39A) viral genomes
(8 mg each) using lipofectamine 2000 according to Manufacturer’s
recommendations (Invitrogen). After 5 h, cells were washed with
PBS and fed with complete DMEM supplemented with 10% FBS
and antibiotics [penicillin/streptomycin (100 mg/ml), ciproﬂoxa-
cin (10 mg/ml)]. Next day, transfected cells were trypsinized and
transferred into a 175 cm2 ﬂasks; and fed with 40 ml complete
media supplemented with antibiotics. Every three days, half of
the media (20 ml) from each ﬂask was discarded and replenished
with new 20 ml complete media. Note that transfected/infected
cells were maintained in the same ﬂask without splitting until
harvest, which is important for obtaining productive and consis-
tent results. At the indicated time points, low-molecular-weight
DNA containing both input and replicated viral DNA was isolated
using Qiagen spin columns (Ziegler et al., 2004), digested with
BamHI and DpnI enzymes, resolved on a 1% agarose gel and
analyzed by Southern blotting.
Preparation of whole-cell extracts for western blotting
SVG-A cells (2106 cells/75 cm2 ﬂask) were transfected/
infected separately with JCV Mad-1 WT and JCV Mad-1 Agno
(F31AF35AF39A) genomic DNA (8 mg each) using lipofectamine
2000 according to Manufacturer’s recommendations (Invitrogen)
as previously described (Sariyer et al., 2011). Whole cell extracts
were prepared at the indicated time points (see the respectiveﬁgure legends) as previously described (Sariyer et al., 2011),
separated on a 15% SDS-PAGE and blotted on a nitrocellulose
membrane (Bio-Rad) for 10 min at 250 mA. The membrane was
then incubated with a primary polyclonal anti-Agno antibody
(1:1000 dilution) for 2 h (Del Valle et al., 2002) and washed with
PBST buffer three times to remove the nonspeciﬁc binding. The
membrane was ﬁnally incubated with a HRP-conjugated second-
ary antibody and developed using an ECL-kit (GE HealthCare)
according to the manufacture’s recommendations (Sadowska
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